This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods of combining primary studies
The baseline FOBT sensitivity was derived from three studies. The value determined for this study was estimated from the value that most closely corresponded to two studies and was within the range of a third study.
Investigation of differences between primary studies
The authors did not investigate the differences between the primary studies.
Results of the review
Over a third of the RAF population were below 25 years of age, nearly three quarters under 35 and over four-fifths under 40. The average age of RAF personnel was within the range 30.5 +/-0.9 years since 1975.
Age specific rates among the general population were applied to the age-sex distribution of the RAF population. The colorectal cancer rate per 100,000 males (females) ranged between 0.26238 (0.22086) for those aged [15] [16] [17] [18] [19] 6 .56314 (5.85549) for those aged 35-39, and 127.200 (91.6895) for those aged 60-64.
From January 1969 to June 1994 there were 103 colorectal cancer cases occurring in the RAF population. The average incidence over this period was 4.04 per annum, which was slightly greater than the current incidence predicted from national data of 3.60 per annum.
The 5-year survival rates for those with colorectal cancer at Duke's stage A, B, C or D at diagnosis, were respectively, 80%, 60%, 30%, and 10%.
The baseline FOBT sensitivity for colorectal cancer was estimated to be 55%. FOBT would have an additional sensitivity of two-thirds the initial value for colorectal cancers diagnosed between one and two years later, and one third of this level for colorectal cancers diagnosed between two and three years later.
The baseline prevalence of FOBT results was assumed to be 5%.
Measure of benefits used in the economic analysis
The measure of benefits used in the economic analysis was the number of cases detected. Multiplying the RAF population by the colorectal cancer incidence gave the number of cases detected. This was then multiplied by the sensitivity of FOBT to detect cancers, which was then multiplied by the lead-time effect to obtain the number of cases potentially detected.
Resource use and costs were not reported separately. The direct costs to the RAF, which in this case was the third party payer, were included in the analysis. The costs included were: the costs of the FOBT; the personnel costs of testing; the costs of subsequent investigation, which included NHS staff costs assumed to be comparable to those for the RAF; and the costs of colonoscopies. It is unclear if further costs were included in the analysis. FOBT costs were obtained from the manufacturers of the tests. Personnel costs of testing were calculated as the full capitation costs of a senior aircraftman for the time taken to undertake one test, with the information being supplied by RAF laboratories. Additional supply and transport costs were assumed to be negligible, as they would involve existing transport channels. Total costs were reported, which were calculated by multiplying the number in each age group by the cost of the FOBT test, and added to the product of the number of positive FOBT and the cost of a colonoscopy. As all costs were incurred over a short time period, discounting was not relevant and hence was not performed. The price year was not explicitly reported.
Statistical analysis of costs
Costs were treated as point estimates (i.e., the data were deterministic).
Indirect Costs
Indirect costs were not included.
Currency

UK pounds sterling ().
Sensitivity analysis
The authors undertook a sensitivity analysis by varying the costs of a full investigation of FOBT positive cases; using a more expensive FOBT test; an improvement in the specificity of FOBT and thus a reduction in the prevalence of positive FOBTs; and a sensitivity of FOBTs of 90%. 
Estimated benefits used in the economic analysis
Cost results
The costs of starting FOBTs at one of the following years were: 
